1433360-12-3

Basic information

• Product Name: (S)-1-[5-tert-butyl-3-(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-pyrrolidin-3-ol
• CAS NO: 1433360-12-3
• Molecular Weight: 382.465
• Mol File: 1433360-12-3.mol

Chemical Properties

• CAS DataBase Reference: (S)-1-[5-tert-butyl-3-(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-pyrrolidin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-[5-tert-butyl-3-(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-pyrrolidin-3-ol(1433360-12-3)
• EPA Substance Registry System: (S)-1-[5-tert-butyl-3-(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]-pyrrolidin-3-ol(1433360-12-3)

Safety Data

• Hazardous Substances Data: 1433360-12-3(Hazardous Substances Data)

Upstream product

• 1433363-10-0 5-tert-butyl-7-chloro-3-(4-methoxy benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 100243-39-8 3-hydroxypyrrolidine 
• 133992-53-7 5-amino-1-[(4-methoxyphenyl)methyl]-1,2,3-triazole-4-carboxamide 
• 3282-30-2 pivaloyl chloride 

Relevant articles and documents

Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases

The cannabinoid receptor 2 (CB2) system is described to modulate various pathological conditions, including inflammation and fibrosis. A series of new heterocyclic small-molecule CB2 receptor agonists were identified from a high-throughput screen. Lead optimization gave access to novel, highly potent, and selective (over CB1) triazolopyrimidine derivatives. A preliminary structure-activity relationship was established, and physicochemical properties in this compound class were significantly improved toward better solubility, lipophilicity, and microsomal stability. An optimized triazolopyrimidine derivative, (3S)-1-[5-tert-butyl-3-[(1-cyclopropyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol (39), was tested in a kidney ischemia-reperfusion model, in which it showed efficacy at a dose of 10 mg kg-1 (p.o.). A significant depletion of the three measured kidney markers indicated a protective role of CB2 receptor activation toward inflammatory kidney damage. Compound 39 was also protective in a model of renal fibrosis. Oral treatment with 39 at 3 mg kg-1 per day significantly decreased the amount of fibrosis by ～40 % which was induced by unilateral ureter obstruction.

NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

[1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2

The invention relates to a compound of formula (I), wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament as agonists of the cannabinoid receptor 2.

NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.